Biomimetic nanovesicle vaccines derived from dendritic cells sensitized with whole tumor antigens for melanoma immunotherapy.

ABSTRACT:

Background

Cancer vaccine research has made significant progress in antigen discovery, delivery systems, and combination therapies. However, optimizing antigen selection and delivery remains a current challenge. To address this, we utilized oxidatively treated tumor cells as a source of antigens, effectively enhancing their immunogenicity. Inspired by the antigen delivery capabilities of dendritic cells (DCs) via extracellular vesicles, we developed a novel biomimetic nanovesicle vaccine, diA-MADCVac. This vaccine inherits the targeting ability of DCs, enabling precise antigen delivery to lymph nodes. Moreover, as a carrier, it efficiently delivers both adjuvants and intact tumor antigens, thereby playing a synergistic role in activating the immune system.

Result

By targetin

SUBMITTER: Lu J 

PROVIDER: S-EPMC12554210 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature